|
|
|
|
Rimonabant in
overweight/obesity
|
|
Four studies
including over 6,600 patients:
|
|
RIO North America
and RIO Europe included patients with BMI ≥30, or BMI >27 with
comorbidity (i.e. treated or untreated hypertension and/or treated or
untreated dyslipidaemia)
|
|
•Within the RIO North America trial, patients were
re-randomized at 1 year to remain on the same dose, or switch to placebo
|
|
•RIO North America assessed weight change at 1-year, and
prevention of weight regain at year 2. Waist circumference, dyslipidaemia and
insulin resistance (HOMA) were also evaluated
|
|
•RIO Europe assessed the same parameters as RIO North
America except weight maintenance instead of
prevention of weight regain at year 2 in addition to the same
parameters as RIO North America
|
|
In addition to the
described parameters, RIO Lipids assessed, specific atherogenic parameters
such as adiponectin levels, LDL particle size and density and CRP
|
|
RIO Diabetes was
conducted in overweight/obese patients with type 2 diabetes receiving oral
antidiabetic drug monotherapy, either metformin or sulphonylureas. Primary
end points are the same as for other RIO studies. Other parameters were
evaluated such as HbA1c, fasting and post prandial glucose and
insulin sensitivity, dose of antidiabetic agents and lipid parameters
|